Dr. Baeten's research focuses on the prevention of HIV-1 and other sexually transmitted diseases, including clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV-1 transmission, and behavioral, translational, and implementation science research aimed at optimizing prevention delivery. He led the Partners PrEP Study and MTN-020/ASPIRE, randomized clinical trials that demonstrated the efficacy of oral tenofovir-based pre-exposure prophylaxis (PrEP) and the dapivirine vaginal ring for protection against HIV-1 acquisition. Current projects include a) a multinational open-label trial of the dapivirine vaginal ring for HIV-1 prevention in women (MTN-025/HOPE, through the NIH Microbicides Trials Network), b) implementation science work to deliver antiretroviral treatment and PrEP for HIV-1 prevention, c) studies exploring use of hormonal contraception as a risk factor for HIV-1 (including co-chairing the ECHO Study), and d) collaborative studies of immunologic and virologic factors that influence HIV-1 transmission. He also directs the UW/Fred Hutch Center for AIDS Research (CFAR).

Links

• The UW School of Medicine’s 2015 Alumni Early Achievement Award

Research Interests

• HIV/AIDS and other STDs
• Women
• Africa

Publications

• Pubmed

In The News

How does PrEP, the HIV-prevention medication, work?
Live Science, 08/12/2018

Open-label studies show high uptake of vaginal ring for HIV prevention
Healio, 03/15/2018

Vaginal ring has high uptake, but plenty of questions remain
MD Mag, 03/15/2018